{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:57:54Z","timestamp":1781765874845,"version":"3.54.5"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020707","name":"Janssen Pharmaceutical KK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020707","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020510","name":"Johnson and Johnson KK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo Chemical Pharma Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jiac.2025.102661","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T12:02:03Z","timestamp":1739793723000},"page":"102661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world data on combination treatment with bedaquiline in patients with multidrug-resistant pulmonary tuberculosis in Japan: An interim analysis of post-marketing surveillance"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3056-8066","authenticated-orcid":false,"given":"Mako","family":"Nakaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manami","family":"Kamishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Yamaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6530-7298","authenticated-orcid":false,"given":"Hiroaki","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokiko","family":"Touma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10181","key":"10.1016\/j.jiac.2025.102661_bib1","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/S0140-6736(19)30308-3","volume":"393","author":"Furin","year":"2019","journal-title":"Tuberculosis. Lancet"},{"key":"10.1016\/j.jiac.2025.102661_bib4","article-title":"Pharmaceuticals and medical Devices agency","year":"2014","journal-title":"New drugs approved in FY"},{"key":"10.1016\/j.jiac.2025.102661_bib5","article-title":"Pharmaceuticals and medical Devices agency","year":"2017","journal-title":"New drugs approved in FY"},{"issue":"23","key":"10.1016\/j.jiac.2025.102661_bib6","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","article-title":"The diarylquinoline TMC207 for multidrug-resistant tuberculosis","volume":"360","author":"Diacon","year":"2009","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jiac.2025.102661_bib7","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1313865","article-title":"Multidrug-resistant tuberculosis and culture conversion with bedaquiline","volume":"371","author":"Diacon","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jiac.2025.102661_bib8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.resinv.2019.01.001","article-title":"Safety, efficacy, and pharmacokinetics of bedaquiline in Japanese patients with pulmonary multidrug-resistant tuberculosis: an interim analysis of an open-label, phase 2 study","volume":"57","author":"Tsuyuguchi","year":"2019","journal-title":"Respir Investig"},{"issue":"2","key":"10.1016\/j.jiac.2025.102661_bib13","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1183\/13993003.00724-2015","article-title":"Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis","volume":"47","author":"Pym","year":"2016","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.jiac.2025.102661_bib14","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/cid\/ciab335","article-title":"Effectiveness and cardiac safety of bedaquiline-based therapy for drug-resistant tuberculosis: a prospective cohort study","volume":"73","author":"Brust","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jiac.2025.102661_bib15","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00544-2018","article-title":"Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa","volume":"51","author":"Olayanju","year":"2018","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.jiac.2025.102661_bib16","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01799-2016","article-title":"Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis","volume":"49","author":"Guglielmetti","year":"2017","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.jiac.2025.102661_bib17","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00387-2017","article-title":"Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study","volume":"49","author":"Borisov","year":"2017","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.jiac.2025.102661_bib22","first-page":"1","article-title":"Mycobacterium Testing Method Review Committee. Shortening of treatment for multidrug-resistant tuberculosis, standard for tuberculosis care: direction to include treatment for less than 18 months","volume":"98","year":"2023","journal-title":"Kekkaku"},{"key":"10.1016\/j.jiac.2025.102661_bib23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jgar.2021.02.017","article-title":"Bedaquiline: current status and future perspectives","volume":"25","author":"Khoshnood","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"10.1016\/j.jiac.2025.102661_bib24","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00934-2018","article-title":"Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review","volume":"52","author":"Pontali","year":"2018","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.jiac.2025.102661_bib26","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01462-2017","article-title":"Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence","volume":"50","author":"Pontali","year":"2017","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.jiac.2025.102661_bib27","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00537-2018","article-title":"QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study","volume":"52","author":"Guglielmetti","year":"2018","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.jiac.2025.102661_bib28","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02467-2017","article-title":"Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea","volume":"51","author":"Kim","year":"2018","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.jiac.2025.102661_bib29","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01181-2019","article-title":"A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis","volume":"55","author":"Olayanju","year":"2020","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.jiac.2025.102661_bib30","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1473-3099(20)30770-2","article-title":"QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial","volume":"21","author":"Dooley","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.jiac.2025.102661_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TNMI7-0042-2017","article-title":"Therapy of multidrug-resistant and extensively drug-resistant tuberculosis","volume":"5","author":"Seaworth","year":"2017","journal-title":"Microbiol Spectr"},{"issue":"152","key":"10.1016\/j.jiac.2025.102661_bib32","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0035-2019","article-title":"Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives","volume":"28","author":"Pontali","year":"2019","journal-title":"Eur Respir Rev"},{"issue":"6","key":"10.1016\/j.jiac.2025.102661_bib33","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis","volume":"40","author":"Sotgiu","year":"2012","journal-title":"Eur Respir J"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25000583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25000583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:49:21Z","timestamp":1762368561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X25000583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1341321X25000583"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102661","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world data on combination treatment with bedaquiline in patients with multidrug-resistant pulmonary tuberculosis in Japan: An interim analysis of post-marketing surveillance","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102661","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102661"}}